Form 4: Cytokinetics Executive Sung Lee Reports Stock Transactions Following PSU Vesting

Cytokinetics' EVP and Chief Financial Officer, Sung Lee, reported the acquisition and disposal of company stock following the vesting of Performance Stock Units.

Summary

• Sung Lee, the EVP and Chief Financial Officer of Cytokinetics, reported transactions involving the company's common stock on December 3, 2024.
• These transactions occurred due to the vesting of Performance Stock Units (PSUs).
• Mr. Lee acquired 4,303 shares of common stock upon the vesting of PSUs.
• He also had 1,536 shares withheld to cover tax obligations related to the vesting.
• Additionally, 4,304 PSUs were granted, which have met their performance conditions but remain subject to time-based vesting, and will vest on December 3, 2025.
• Following these transactions, Mr. Lee beneficially owns 41,755 shares of Cytokinetics common stock.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions, which are neither positive nor negative for the company's overall outlook. It is a neutral event.

Future Outlook

The remaining 4,304 PSUs will vest on December 3, 2025.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common practice in publicly traded companies. It reflects the company's compensation structure and is not indicative of any specific industry trend.

Comparison to Industry Standards

• Stock-based compensation, including PSUs, is a common practice among publicly traded biotech companies like Cytokinetics, such as Amgen, Biogen, and Gilead Sciences.
• The vesting schedules and tax withholding practices are generally consistent with industry norms for executive compensation.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for company insiders.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation practices.
• The vesting of PSUs is part of the company's compensation strategy to align executive interests with shareholder value.

Next Steps

• The remaining 4,304 PSUs will vest on December 3, 2025.

Key Dates

Keywords

Cytokinetics, Stock Transactions, Performance Stock Units, PSUs, Vesting, Executive Compensation, Form 4, Insider Trading